Testimonials / Success Stories


Thank you for the level of business professionalism by your clinical research team in regards to the prospective clinical study on the structurally optimized XXX-T cell therapy for refractory/recurrent B lymphocyte malignancies.

Chang Qi

Successes: 2018 Firsts

  • July 2018 – CSC completed the first Omeprazole Enteric Capsule BE (Bio-Equivalence) study in China.
  • August 2018 – CSC was the first Chinese CRO to submit a Global Clinical Trial Application for a new Precision Therapy drug to the NMPA; we supported Sponsor with CDE communication meetings and were entrusted with the subsequent phase I study.
  • September 2018 – Prepared for the testing of the first new Precision Therapy Oncology drug in China; dose research conducted in China and US simultaneously; brought local experts together for protocol discussion meetings.
  • October 2018 – Entrusted with the first Bispecific Antibody Phase I Study in China.
  • December 2018 - Participated in the clinical development of the first domestic PD-1 antibody to obtained regulatory approval in China.

More About the Clinical Service Center CRO



Our senior managers and executives were trained in the West, have worked for big Western pharmaceutical companies, and are committed to bringing the best clinical practices to China.

Learn more


Company News

For more than a decade, Clinical Service Center-“CSC” (formerly Beijing Clinical Service Center – “BCSC”) has been conducting top-quality clinical trial services in China for pharmaceutical, biotech, and medical device companies the world over.

Learn more


Full Service Plus

At CSC we define our business scope as “full-service plus” because we go above and beyond the requirements of a traditional full-service CRO to provide you with the end-to-end services you require to get your product in to the China market.

Learn more

Sign up to Receive Company News & China Market Intelligence Updates